

\$250,000 per year (2 years and \$125,000 for R21's). Because the nature and scope of the research proposed might vary, it is anticipated that the size of each award will also vary. Although the financial plans of the IC(s) provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications. At this time, it is not known if this RFA will be reissued.

Contact: Prospective applicants are asked to submit, by February 15, 2002, a letter of Intent to be sent to: Toby Behar, Ph.D. Neural Environment National Institute of Neurological Disorders and Stroke 6001 Executive Blvd., Room 2114A Bethesda, MD 20892-9521 Telephone: (301) 496-1431 FAX: (301) 480-2424 Email: tb72Z@nih.gov The PHS 398 research grant application instructions and forms (rev. 5/2001) available at <http://grants.nih.gov/grants/funding/phs398/phs398.html> are to be used in applying for these grants. This version of the PHS 398 is available in an interactive, searchable PDF format. Although applicants are strongly encouraged to begin using the 5/2001 revision of the PHS 398 as soon as possible, the NIH will continue to accept applications prepared using the 4/1998 revision until January 9, 2002. Beginning January 10, 2002, however, the NIH will return applications that are not submitted on the 5/2001 version. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

Deadline: Letter of Intent Receipt Date: February 15, 2002. Application Receipt Date: March 15, 2002.

BARRETT'S ESOPHAGUS, GASTROESOPHAGEAL REFLUX DISEASE AND ADENOCARCINOMA OF THE ESOPHAGUS: RFA-DK-02-015

Purpose: This initiative is designed to stimulate and solicit studies to broadly address the problem of Barrett's esophagus and its etiology and relationship to gastroesophageal reflux disease (GERD) and its link to the rising incidence of adenocarcinoma of the esophagus. The specific areas of emphasis of this initiative will include novel approaches for molecular characterization of Barrett's metaplasia and dysplasia in comparison to normal squamous and intestinal epithelium, identification of esophageal stem cells and the factors responsible for specific differentiation pathways into either squamous or intestinal epithelium, regeneration of squamous mucosa, the molecular precursors or predictors of dysplasia, identification of serum biomarkers of metaplasia or dysplasia, development of suitable animal models to study pathogenesis, chemoprevention or treatment strategies, and clinical studies aimed at revealing environmental or genetic risk factors or the role of gastroesophageal reflux in Barrett's esophagus. In addition to hypothesis-driven R01 projects, this initia-

tive will encourage development of new research tools through Exploratory/Developmental Grants (R21).

Term/Amount: The NIDDK and NCI intend to commit approximately \$2.5 million in FY 2002 to fund approximately six new research project grants (R01) and six new exploratory research grants (R21) in response to this RFA. Although the financial plans of the NIDDK and NCI provide support for this program, awards pursuant to this RFA are contingent upon the availability of funds and the receipt of a sufficient number of applications of outstanding scientific and technical merit.

Contact: The letter of intent is to be sent to: Francisco O. Calvo, Ph.D., Chief, Review Branch Division of Extramural Activities, NIDDK 6707 Democracy Boulevard, Rm. 752 MSC 5452 Bethesda, MD 20892-5452 (for express/courier service: Bethesda, MD 20817) Telephone: (301) 594-8885 FAX: (301) 480-3505 The PHS 398 research grant application instructions and forms (rev. 5/2001) at <http://grants.nih.gov/grants/funding/phs398/phs398.html> are to be used in applying for these grants. This version of the PHS 398 is available in an interactive, searchable PDF format. For further assistance contact GrantsInfo, Telephone 301/435-0714, Email: GrantsInfo@nih.gov.

Deadline: Letter of Intent Receipt Date: February 20, 2002. Application Receipt Date: March 20, 2002.

MULTICENTER CLINICAL TRIAL OF FOCAL GLOMERULOSCLEROSIS IN CHILDREN AND YOUNG ADULTS: DK-02-013

Purpose: The Division of Kidney, Urologic and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites cooperative agreement (U01) applications for Regional Clinical Coordinating Centers and a Data Coordinating Center to conduct a randomized clinical trial of cyclosporin or novel immunomodulatory agents in children and young adults with Focal Segmental Glomerulosclerosis (FSGS).

Term/Amount: (ICs should modify as necessary) The NIDDK plans to make four awards for Regional Clinical Coordinating Centers and one award for a Data Coordinating Center. Approximately \$1,000,000 total cost (direct plus facilities and administrative costs) is expected to be available during year one of the study. In each subsequent year \$ 2,000,000 will be available under this RFA. It is anticipated that the award for each Regional Clinical Coordinating Center will be about \$200,000 total cost in year one and \$400,000 total cost in each subsequent year. The award for the Data Coordinating Center will be about \$200,000 total cost in year one and approximately \$400,000 total cost in each subsequent year of the program. The number of awards to be made is dependent on